# Hasten

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hasten

- Industry: Biotechnology
- Headquarters: Hefei, China
- Website: www.hastenpharma.com
- Latest round: Series A (Mar 4, 2022)
- Investors on record: 3

## About

Founded in 2020 and based in Hefei, China, Hasten is a biopharmaceutical company that focuses on the research and development of drugs in the field of chronic disease and age-related disease management. The company has offices in cities such as Beijing, Shanghai and Guangzhou. As of 2023, it has more than 700 employees. In April 2023, Hasten raised USD 315 million series B funding co-led by new investor Mubadala Capital and returning investor CBC Group.

The company relies on the healthcare platform and resources of its shareholder, Kangqiao Capital, to enrich its product mix and product pipeline in the area of chronic disease and age-related disease management. The company's main products include Adenidine, Yidabi and Basexin, etc. Its products are used in areas such as cardiovascular and metabolism. The company also provides other services including pharmaceutical commissioning, pharmaceutical wholesaling, testing and inspection services, pharmaceutical import and export, and health food production and sales.

## Funding rounds

- Series A, Mar 4, 2022 — CBC Group, Hefei State-Owned Assets Holding, Ruimu Investment

## Investors

- CBC Group (https://capitalatlas.ai/funds/cbc-group) — Series A
- Hefei State-Owned Assets Holding (https://capitalatlas.ai/funds/hefei-state-owned-assets-holding) — Series A
- Ruimu Investment — Series A